Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02491567
Other study ID # 62/17-2-2014
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2014
Est. completion date April 2018

Study information

Verified date September 2019
Source Aristotle University Of Thessaloniki
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hashimoto Thyroiditis (HT) and Graves Disease (GD) are known to be caused by abnormal immune response against self cells and tissues. Epigenetics is a novel field of biology studying the mechanisms by which the environment interacts with the genotype to produce a variety of phenotypes through modifications to chromatin that do not directly alter the DNA sequence. A very limited number of epigenetic studies have been published in patients with HT and GD so far. Therefore, the purpose of this study is to analyze DNA methylation status in White Blood Cells (WBCs) within the promoter regions of genomic sites that have been previously identified as susceptibility loci or sites for autoimmune thyroid disease, such as the CD40L, FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 genes.


Description:

Hashimoto Thyroiditis (HT) and Graves Disease (GD) are known to be caused by abnormal immune response against self cells and tissues. HT involves a cell-mediated autoimmune destruction of the thyroid leading to hypothyroidism. GD is caused by a process in which immune cells make stimulating antibodies against the thyroid stimulating hormone (TSH) receptor on the thyroid gland, thus leading to hyperthyroidism. Although there is substantial evidence that genetic factors increase the risk for developing autoimmune diseases, monozygotic twins still remain discordant for disease (disease concordance is never 100%), thus suggesting a role for environmental factors and epigenetics.

Epigenetics is a novel field of biology studying the mechanisms by which the environment interacts with the genotype to produce a variety of phenotypes through modifications to chromatin that do not directly alter the DNA sequence. These modifications have been associated with altered gene expression and silencing of repetitive elements and can be inherited mitotically. Epigenetic mechanisms include DNA methylation, histone modifications, or miRNA post-transcriptional regulation. DNA methylation involves the covalent addition of a methyl group to the carbon-5 position in the CpG dinucleotide from the methyl donor S-adenosylmethionine and is mediated by a group of enzymes called DNA methyltransferases (DNMTs). CpG dinucleotides are typically grouped together in regions known as CGIs (islands). CGIs can be found in the promoter regions of genes, and CpG methylation of these gene promoters is associated with transcriptional silencing. In contrast, hypermethylated genes have been found to be transcriptionally active.

A very limited number of epigenetic studies have been published in patients with HT and GD so far. Therefore, the purpose of this study is to analyze DNA methylation status in White Blood Cells (WBCs) within the promoter regions of genomic sites that have been previously identified as susceptibility loci or sites for autoimmune thyroid disease, such as the CD40L, FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 genes.

Initially, recruitment of patients and controls as well as blood sample collection will be done. A complete physical examination will also be performed in all participants included in the study, and a detailed personal, family, gestational and perinatal history will be obtained as well before inclusion. Blood samples by all participants will be collected and centrifuged and then White Blood Cells (WBCs), plasma and serum will be separated and stored in a deep freezer.

Laboratory analyses will follow. DNA will be isolated from peripheral leukocytes using the QIAamp DNA Blood Mini Kit, according to the manufacturer's instructions. It will then be treated with sodium bisulfite using the Zymo EZ DNA Methylation-Gold Kit, again according to the manufacturer's protocol. Therefore, unmethylated cytosines will be converted into uracyls, whereas methylated cytosines will remain unchanged. Quantification of the methylation status of DNA at the gene promoter regions under study will be made, using specific primers that detect modified DNA, by real-time PCR and analysis of the melting curves of the selected fragments of DNA. Amplicons will also be analyzed by electrophoresis and visualized by ultraviolet trans-illumination.

An electronic Data Base will be constructed and Statistical Analysis will follow. Results and Conclusions will be published in peer-review journals and presented in International Meetings.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date April 2018
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years to 18 Years
Eligibility Inclusion Criteria:

For HT:

A positive titers of antithyroid peroxidase (anti-TPO) or antithyroglobulin (anti-Tg) antibodies and at least one of:

- Abnormal thyroid function that requires substitution treatment with L-thyroxine (TSH > 5 µIU/ml and decreased or normal levels of fT4 or fT3)

- Increased volume of thyroid gland (goiter)

- Morphological changes on ultrasound of the thyroid gland

For GD:

- A positive titers of thyroid stimulating antibodies (anti-TSI) and

- Decreased TSH levels and increased levels of fT4 or fT3

For Controls:

- Otherwise healthy children and adolescents, age- and gender-matched with patients

- Absence of previously known chronic disease of autoimmune aetiology or atopy (including those with a history of chronic treatment with antihistamines, anti-inflammatory, corticosteroids or anti-epileptic drugs)

- Absence of a family history of autoimmune disease in first-degree relatives

Exclusion Criteria:

- Not Caucasian origin or affinity among participants

- Age of diagnosis above 18 years

- Disease duration below 3 months

Study Design


Locations

Country Name City State
Greece Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki Thessaloniki

Sponsors (1)

Lead Sponsor Collaborator
Aristotle University Of Thessaloniki

Country where clinical trial is conducted

Greece, 

References & Publications (13)

Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM, Herold KC. Detection of ß cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19018-23. doi: 10.1073/pnas.1111008108. Epub 2011 Nov 9. — View Citation

Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS; Type 1 Diabetes Genetics Consortium. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009 Jun;41(6):703-7. doi: 10.1038/ng.381. Epub 2009 May 10. — View Citation

Cooper JD, Simmonds MJ, Walker NM, Burren O, Brand OJ, Guo H, Wallace C, Stevens H, Coleman G; Wellcome Trust Case Control Consortium, Franklyn JA, Todd JA, Gough SC. Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet. 2012 Dec 1;21(23):5202-8. doi: 10.1093/hmg/dds357. Epub 2012 Aug 24. — View Citation

Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev. 2013 Jan;29(1):8-18. doi: 10.1002/dmrr.2375. Review. — View Citation

Davies TF, Latif R, Yin X. New genetic insights from autoimmune thyroid disease. J Thyroid Res. 2012;2012:623852. doi: 10.1155/2012/623852. Epub 2012 Feb 28. — View Citation

Fradin D, Le Fur S, Mille C, Naoui N, Groves C, Zelenika D, McCarthy MI, Lathrop M, Bougnères P. Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes. PLoS One. 2012;7(5):e36278. doi: 10.1371/journal.pone.0036278. Epub 2012 May 2. — View Citation

Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev. 2008 Oct;29(6):697-725. doi: 10.1210/er.2008-0015. Epub 2008 Sep 5. Review. — View Citation

Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun. 2013 Mar;41:1-5. doi: 10.1016/j.jaut.2013.01.010. Epub 2013 Feb 1. Review. — View Citation

MacFarlane AJ, Strom A, Scott FW. Epigenetics: deciphering how environmental factors may modify autoimmune type 1 diabetes. Mamm Genome. 2009 Sep-Oct;20(9-10):624-32. doi: 10.1007/s00335-009-9213-6. Epub 2009 Aug 22. Review. — View Citation

Quintero-Ronderos P, Montoya-Ortiz G. Epigenetics and autoimmune diseases. Autoimmune Dis. 2012;2012:593720. doi: 10.1155/2012/593720. Epub 2012 Mar 22. — View Citation

Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, Daunay A, Busato F, Mein CA, Manfras B, Dias KR, Bell CG, Tost J, Boehm BO, Beck S, Leslie RD. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011 Sep;7(9):e1002300. doi: 10.1371/journal.pgen.1002300. Epub 2011 Sep 29. — View Citation

Weetman AP. Determinants of autoimmune thyroid disease. Nat Immunol. 2001 Sep;2(9):769-70. — View Citation

Yin X, Latif R, Tomer Y, Davies TF. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci. 2007 Sep;1110:193-200. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary DNA methylation status of CpGs within gene promoters Percentage of DNA methylation of CpGs within the CD40L, FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 promoter genes in White Blood Cells (WBCs). 1 month
Secondary Age Age of each participant 1 day
Secondary Age of disease onset Age of disease diagnosis 1 day
Secondary Sex Male or female 1 day
Secondary Body mass index Weight in kg / height in m * height in m 1 day
Secondary Pubertal stage Prepubertal or pubertal stage 1 day
Secondary Antibodies titre Titre of antiTPO, antiTg, anti-TSI antibodies in blood 1 day
Secondary Thyroid volume Volume of the thyroid gland in total (both lobes) 1 day
Secondary Treatment dose Dose of Levothyroxine/thiamazole per kg of body weight /per day (if applicable) 1 day
Secondary B12 Levels of B12 in blood 1 day
Secondary Folic acid Levels of folic acid in blood 1 day
Secondary IgA, IgG, IgM, IgE immunoglobulins Levels of IgA, IgG, IgM, IgE immunoglobulins in blood 1 day
Secondary History of infections Number of previous febrile viral /bacterial infections per year 1 day
Secondary History of medications Number of previous medications per year 1 day
Secondary Other autoimmune diseases Diagnosis of co-existing autoimmune disease (except autoimmune thyroid disease) 1 day
Secondary Family history of autoimmune thyroid (or other) disease Family history of autoimmune thyroid (or other) disease or not 1 day
Secondary Parental educational level Elementary school, high school or university graduate 1 day
Secondary Type of Residence Urban or rural residence 1 day
Secondary Parental smoking Total number of cigarettes per day during their child's life separately for each parent (if applicable) 1 day
Secondary Previous births Number of previous births 1 day
Secondary Month of birth Month of birth (from January to December) 1 day
Secondary Delivery type Cesarean section or vaginal delivery 1 day
Secondary Birth weight Birth weight 1 day
Secondary Gestation duration Duration of pregnancy 1 day
Secondary Medications during pregnancy Number of medications of any type received during pregnancy (if applicable) 1 day
Secondary Maternal smoking during pregnancy Total number of cigarettes per day during pregnancy (if applicable) 1 day
Secondary Maternal alcohol consumption during pregnancy Total number of glasses of alcohol consumption per day during pregnancy (if applicable) 1 day
Secondary Pre-eclampsia (during pregnancy) Diagnosis of pre-eclampsia (during pregnancy) or not 1 day
Secondary Gestational diabetes (during pregnancy) Diagnosis of gestational diabetes (during pregnancy) or not 1 day
Secondary Vaginal bleeding (during pregnancy) Presence of vaginal bleeding (during pregnancy) or not 1 day
Secondary Maternal febrile infection (during pregnancy) Diagnosis of maternal febrile infection (during pregnancy) or not 1 day
Secondary Duration of breastfeeding Duration of breastfeeding until discontinuance 1 day
Secondary History of phototherapy History of phototherapy during neonatal period (or not) 1 day
Secondary APGAR score APGAR score at 1st and 5th min of life 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05774535 - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Completed NCT02973802 - ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy Phase 1
Terminated NCT01320813 - Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy N/A
Completed NCT00432146 - Effect of Lugol's Solution in the Patients With Graves' Disease N/A
Recruiting NCT06081439 - Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
Not yet recruiting NCT06327828 - Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Active, not recruiting NCT04135573 - The Relationship Between NK Cell and Graves' Disease
Recruiting NCT06134219 - Course for Brain Fatigue After Graves' Disease Controlled Study N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Completed NCT03009357 - Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
Recruiting NCT05510609 - Three-dimensional Ultrasonography Thyroid Volume Measurement. N/A
Not yet recruiting NCT06426758 - Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Recruiting NCT05907668 - A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease Phase 2
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting NCT03303053 - Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Phase 3
Recruiting NCT05461820 - Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease Phase 4
Recruiting NCT06309316 - The Impact of Person Centred Care (PCC) in Grave's Disease N/A